FINWIRES · TerminalLIVE
FINWIRES

Needham Upgrades Rocket Pharmaceuticals to Buy From Hold, Price Target is $9

By

Rocket Pharmaceuticals (RCKT) has an average rating of overweight and mean price target of $8.85, according to analysts polled by FactSet.

What else is happening in Research?